↓ Skip to main content

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Overview of attention for article published in Annals of Oncology, May 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

blogs
1 blog
twitter
7 tweeters

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
Published in
Annals of Oncology, May 2019
DOI 10.1093/annonc/mdz082
Pubmed ID
Authors

C. Santos, D. Azuara, J.M. Viéitez, D. Páez, E. Falcó, E. Élez, C. López-López, M. Valladares, L. Robles-Díaz, P. García-Alfonso, C. Bugés, G. Durán, A. Salud, V. Navarro, G. Capellá, E. Aranda, R. Salazar

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 25%
Student > Ph. D. Student 3 25%
Professor 1 8%
Professor > Associate Professor 1 8%
Other 1 8%
Other 0 0%
Unknown 3 25%
Readers by discipline Count As %
Medicine and Dentistry 3 25%
Pharmacology, Toxicology and Pharmaceutical Science 2 17%
Nursing and Health Professions 1 8%
Biochemistry, Genetics and Molecular Biology 1 8%
Unknown 5 42%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2020.
All research outputs
#1,559,132
of 14,249,443 outputs
Outputs from Annals of Oncology
#1,017
of 5,860 outputs
Outputs of similar age
#48,083
of 262,773 outputs
Outputs of similar age from Annals of Oncology
#40
of 99 outputs
Altmetric has tracked 14,249,443 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,860 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,773 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.